HRP20140535T1 - Rekombinantni fsh ukljuäśujuä†i alfa 2,3- i alfa 2,6-sialilaciju - Google Patents
Rekombinantni fsh ukljuäśujuä†i alfa 2,3- i alfa 2,6-sialilaciju Download PDFInfo
- Publication number
- HRP20140535T1 HRP20140535T1 HRP20140535AT HRP20140535T HRP20140535T1 HR P20140535 T1 HRP20140535 T1 HR P20140535T1 HR P20140535A T HRP20140535A T HR P20140535AT HR P20140535 T HRP20140535 T HR P20140535T HR P20140535 T1 HRP20140535 T1 HR P20140535T1
- Authority
- HR
- Croatia
- Prior art keywords
- sialylation
- mol
- alpha
- recombinant fsh
- rfsh
- Prior art date
Links
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 4
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 4
- 230000009450 sialylation Effects 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
- C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (7)
1. Rekombinantni FSH (rFSH) uključujući α2,3- i α2,6-sialilaciju gdje 60% ili više od ukupne sialilacije je α2,3-sialilacija i od 5 do 40% od ukupne sialilacije je α2,6-sialilacija; pri čemu rekombinantni FSH ima sadržaj sijalinske kiseline [izražen terminom omjera molova sijalinske kiseline prema molovima proteina] od 10 mol/mol do 15 mol/mol.
2. Rekombinantni FSH prema patentnom zahtjevu 1 koji nadalje uključuje α2,8-sialilaciju.
3. Farmaceutski pripravak koji sadrži rFSH uključujući α2,3-sialilaciju i α2,6-sialilaciju gdje 60% ili više od ukupne sialilacije je α2,3-sialilacija i od 5 do 40% od ukupne sialilacije je α2,6-sialilacija; te ima sadržaj sijalinske kiseline [izražen terminom omjera molova sijalinske kiseline prema molovima proteina] od 10 mol/mol do 16 mol/mol.
4. Farmaceutski pripravak koji sadrži rFSH prema patentnom zahtjevu 2.
5. Farmaceutski pripravak prema patentnom zahtjevu 3 ili 4 koji nadalje sadrži hCG i/ili LH.
6. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 3 do 5 za uporabu u liječenju neplodnosti.
7. Postupak proizvodnje rFSH prema bilo kojem od patentnih zahtjeva 1 ili 2 koji sadrži korak proizvodnje ili ekspresije rFSH u ljudskoj staničnoj liniji.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4542408P | 2008-04-16 | 2008-04-16 | |
| EP08251528 | 2008-04-25 | ||
| PCT/GB2009/000978 WO2009127826A1 (en) | 2008-04-16 | 2009-04-16 | Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140535T1 true HRP20140535T1 (hr) | 2014-07-18 |
Family
ID=39717519
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140535AT HRP20140535T1 (hr) | 2008-04-16 | 2014-06-09 | Rekombinantni fsh ukljuäśujuä†i alfa 2,3- i alfa 2,6-sialilaciju |
| HRP20161520TT HRP20161520T1 (hr) | 2008-04-16 | 2016-11-16 | Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6-sialilaciju |
| HRP20170958TT HRP20170958T1 (hr) | 2008-04-16 | 2017-06-26 | Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6- sialilaciju |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161520TT HRP20161520T1 (hr) | 2008-04-16 | 2016-11-16 | Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6-sialilaciju |
| HRP20170958TT HRP20170958T1 (hr) | 2008-04-16 | 2017-06-26 | Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6- sialilaciju |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US8951967B2 (hr) |
| EP (7) | EP3098234A1 (hr) |
| JP (7) | JP2011519359A (hr) |
| KR (5) | KR20160056960A (hr) |
| CN (3) | CN105906703A (hr) |
| AR (1) | AR071479A1 (hr) |
| AU (5) | AU2009237479B2 (hr) |
| BR (1) | BRPI0910461B8 (hr) |
| CA (1) | CA2725257A1 (hr) |
| CY (1) | CY1115413T1 (hr) |
| DK (4) | DK2808340T3 (hr) |
| ES (3) | ES2468318T3 (hr) |
| FR (1) | FR17C1020I2 (hr) |
| HK (2) | HK1146284A1 (hr) |
| HR (3) | HRP20140535T1 (hr) |
| HU (5) | HUE033830T2 (hr) |
| IL (2) | IL208538A (hr) |
| LT (4) | LT2808340T (hr) |
| MX (3) | MX2010011343A (hr) |
| NO (2) | NO2017025I1 (hr) |
| NZ (1) | NZ588381A (hr) |
| PL (4) | PL2268666T3 (hr) |
| PT (4) | PT3144318T (hr) |
| RU (3) | RU2682270C2 (hr) |
| SA (1) | SA109300228B1 (hr) |
| SI (4) | SI2808340T1 (hr) |
| TW (1) | TWI488640B (hr) |
| WO (1) | WO2009127826A1 (hr) |
| ZA (1) | ZA201007373B (hr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
| TWI532495B (zh) | 2009-10-05 | 2016-05-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| EP2417982A1 (en) | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
| WO2012016576A1 (en) * | 2010-08-04 | 2012-02-09 | Glycotope Gmbh | Improved recombinant human follicle-stimulating hormone |
| WO2012042381A1 (en) | 2010-09-29 | 2012-04-05 | Ferring B.V. | Composition for controlled ovarian stimulation |
| JP5918697B2 (ja) | 2010-10-15 | 2016-05-18 | Ｊｃｒファーマ株式会社 | 糖鎖の非還元末端がマンノース残基である糖蛋白質の製造方法 |
| CA2831486A1 (en) | 2011-03-31 | 2012-10-04 | Ferring B.V. | Pharmaceutical preparation |
| EP2717904A1 (en) | 2011-06-06 | 2014-04-16 | Ferring BV | Pharmaceutical preparation comprising recombinant fsh |
| JO3092B1 (ar) | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
| AU2012340501A1 (en) * | 2011-12-19 | 2013-07-11 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
| EP2848687B1 (en) * | 2012-04-27 | 2017-09-13 | JCR Pharmaceuticals Co., Ltd. | Novel expression vector |
| EP2824176A1 (en) | 2013-07-11 | 2015-01-14 | Siamed'xpress | Methods for producing sialylated therapeutic proteins |
| JP6652334B2 (ja) * | 2014-05-31 | 2020-02-19 | Ｊｃｒファーマ株式会社 | ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地 |
| EP3237608B1 (en) * | 2014-12-22 | 2019-10-09 | F. Hoffmann-La Roche AG | Cmp-dependent sialidase activity |
| JP7079094B2 (ja) | 2015-04-17 | 2022-06-01 | フェリング ベスローテン フェンノートシャップ | 不妊症の処置のための組成物 |
| WO2016207353A1 (en) * | 2015-06-26 | 2016-12-29 | Ferring B.V. | Methods of purification and/or viral inactivation |
| EP3205719A1 (en) * | 2016-02-15 | 2017-08-16 | CEVEC Pharmaceuticals GmbH | Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins |
| GB201603280D0 (en) | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
| EP3382014A1 (en) * | 2017-03-29 | 2018-10-03 | CEVEC Pharmaceuticals GmbH | Recombinant glycoproteins with reduced antennary fucosylation |
| ES2904787T3 (es) | 2017-09-01 | 2022-04-06 | Ferring Bv | Composición para la estimulación ovárica controlada |
| US20210038694A1 (en) | 2018-04-30 | 2021-02-11 | Ferring B.V. | Composition for controlled ovarian stimulation |
| KR20210079276A (ko) | 2018-10-17 | 2021-06-29 | 훼링 비.브이. | 제어된 난소 자극을 위한 조성물 및 방법 |
| WO2021081670A1 (en) * | 2019-11-01 | 2021-05-06 | The University Of British Columbia | Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins |
| TW202237173A (zh) | 2020-12-09 | 2022-10-01 | 荷蘭商菲林公司 | 用於受控的卵巢刺激之組成物及方法 |
| WO2023186331A1 (en) | 2022-04-01 | 2023-10-05 | Ferring B.V. | Mixed protocol for treatment of infertility |
| WO2023227761A1 (en) | 2022-05-26 | 2023-11-30 | Ferring B.V. | Compositions and methods for treatment of infertility in males |
| WO2024008971A1 (en) | 2022-07-08 | 2024-01-11 | Ferring B.V. | Compositions and methods for intrauterine insemination (iui) |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1206302B (it) | 1987-06-26 | 1989-04-14 | Serono Cesare Ist Ricerca | Ormone follicolo-stimolante urinario |
| US5541083A (en) | 1989-10-24 | 1996-07-30 | The Regents Of The University Of California | Method for producing secretable glycosyltransferases and other golgi processing enzymes |
| ES2333425T5 (es) | 1995-06-15 | 2012-08-28 | Crucell Holland B.V. | Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica |
| JP3559652B2 (ja) * | 1996-06-25 | 2004-09-02 | グローリー工業株式会社 | 売上精算システムの管理装置 |
| IL122732A0 (en) * | 1997-01-15 | 1998-08-16 | Akzo Nobel Nv | Liquid gonadotropin-containing formulation its preparation and a device containing same |
| WO1998031826A1 (en) | 1997-01-16 | 1998-07-23 | Cytel Corporation | Practical in vitro sialylation of recombinant glycoproteins |
| JPH1111665A (ja) | 1997-06-28 | 1999-01-19 | Shibuya Kogyo Co Ltd | 無菌エア搬送コンベヤ装置 |
| TWI235158B (en) * | 1997-09-01 | 2005-07-01 | Kirin Brewery | Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same |
| ATE332705T1 (de) | 1999-05-07 | 2006-08-15 | Applied Research Systems | Verwendung von in der mittlere oder späte follikuläre phase verabreichte lh zur behandlung von anovulatorischen frauen |
| JP2002011665A (ja) | 2000-06-28 | 2002-01-15 | Sintokogio Ltd | ショットブラスト装置モニタシステム |
| IL140110A0 (en) | 2000-12-05 | 2002-02-10 | Applied Research Systems | Improvement of homogeneity and secretion of recombinant proteins in mammalian systems |
| RS32804A (en) * | 2001-10-22 | 2007-02-05 | Applied Research Systems Ars Holding N.V., | Gonadotrophins for folliculogenesis |
| CA2465007C (en) | 2001-10-29 | 2012-01-17 | Crucell Holland B.V. | Methods and means for producing proteins with predetermined post-translational modifications |
| KR100979025B1 (ko) | 2001-12-07 | 2010-08-30 | 크루셀 홀란드 비.브이. | 바이러스, 바이러스 단리물 및 백신의 생산 |
| US20040248784A1 (en) * | 2003-06-03 | 2004-12-09 | Marco Filicori | Unitary combinations of FSH and hCG |
| EP1694351A2 (en) * | 2003-12-03 | 2006-08-30 | Neose Technologies, Inc. | Glycopegylated follicle stimulating hormone |
| ES2350298T3 (es) | 2004-02-04 | 2011-01-20 | Centre National De La Recherche Scientifique | Procedimiento para el cribado de anticuerpos específicos de glicoforma. |
| JP4913604B2 (ja) | 2004-02-13 | 2012-04-11 | グリコトープ ゲーエムベーハー | 高活性糖タンパク質−製造条件、及びその効率的製造方法 |
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
| TWI532495B (zh) * | 2009-10-05 | 2016-05-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| EP2417982A1 (en) | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
| US8790322B2 (en) | 2010-08-03 | 2014-07-29 | King Saud University | Stoma coat |
| WO2012016576A1 (en) | 2010-08-04 | 2012-02-09 | Glycotope Gmbh | Improved recombinant human follicle-stimulating hormone |
| WO2012042381A1 (en) | 2010-09-29 | 2012-04-05 | Ferring B.V. | Composition for controlled ovarian stimulation |
| CA2831486A1 (en) | 2011-03-31 | 2012-10-04 | Ferring B.V. | Pharmaceutical preparation |
| EP2717904A1 (en) | 2011-06-06 | 2014-04-16 | Ferring BV | Pharmaceutical preparation comprising recombinant fsh |
| JO3092B1 (ar) | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
| BR112016023668A2 (pt) | 2014-04-18 | 2017-10-17 | Glycotope Gmbh | hiperestimulação ovariana controlada com hormônio de estimulação de folículo humano recombinante aperfeiçoado |
-
2009
- 2009-04-15 TW TW098112483A patent/TWI488640B/zh active
- 2009-04-16 PL PL09733497T patent/PL2268666T3/pl unknown
- 2009-04-16 BR BRPI0910461A patent/BRPI0910461B8/pt active IP Right Grant
- 2009-04-16 ES ES09733497.3T patent/ES2468318T3/es active Active
- 2009-04-16 KR KR1020167012148A patent/KR20160056960A/ko not_active Application Discontinuation
- 2009-04-16 EP EP16179121.5A patent/EP3098234A1/en active Pending
- 2009-04-16 PT PT161949250T patent/PT3144318T/pt unknown
- 2009-04-16 EP EP14178729.1A patent/EP2808340B1/en not_active Revoked
- 2009-04-16 PT PT161581418T patent/PT3045471T/pt unknown
- 2009-04-16 AU AU2009237479A patent/AU2009237479B2/en active Active
- 2009-04-16 HU HUE16158141A patent/HUE033830T2/en unknown
- 2009-04-16 EP EP13193214.7A patent/EP2722339A1/en active Pending
- 2009-04-16 KR KR1020107025581A patent/KR101622944B1/ko active IP Right Grant
- 2009-04-16 PT PT97334973T patent/PT2268666E/pt unknown
- 2009-04-16 KR KR1020187023820A patent/KR20180095140A/ko active Application Filing
- 2009-04-16 JP JP2011504527A patent/JP2011519359A/ja active Pending
- 2009-04-16 RU RU2014141994A patent/RU2682270C2/ru active
- 2009-04-16 SI SI200931547A patent/SI2808340T1/sl unknown
- 2009-04-16 HU HUE14178729A patent/HUE030652T4/en unknown
- 2009-04-16 PL PL16158141T patent/PL3045471T3/pl unknown
- 2009-04-16 CN CN201510933827.2A patent/CN105906703A/zh active Pending
- 2009-04-16 RU RU2010141908/10A patent/RU2537268C2/ru active
- 2009-04-16 PL PL16194925T patent/PL3144318T3/pl unknown
- 2009-04-16 CN CN201510933782.9A patent/CN105906702A/zh active Pending
- 2009-04-16 NZ NZ588381A patent/NZ588381A/en unknown
- 2009-04-16 KR KR1020197022294A patent/KR102108377B1/ko active IP Right Grant
- 2009-04-16 EP EP09733497.3A patent/EP2268666B1/en not_active Revoked
- 2009-04-16 SI SI200932094T patent/SI3144318T1/sl unknown
- 2009-04-16 SI SI200931670A patent/SI3045471T1/sl unknown
- 2009-04-16 CA CA2725257A patent/CA2725257A1/en active Pending
- 2009-04-16 MX MX2010011343A patent/MX2010011343A/es active IP Right Grant
- 2009-04-16 LT LTEP14178729.1T patent/LT2808340T/lt unknown
- 2009-04-16 WO PCT/GB2009/000978 patent/WO2009127826A1/en active Application Filing
- 2009-04-16 ES ES16158141.8T patent/ES2629392T3/es active Active
- 2009-04-16 DK DK14178729.1T patent/DK2808340T3/en active
- 2009-04-16 US US12/988,218 patent/US8951967B2/en active Active
- 2009-04-16 EP EP16194925.0A patent/EP3144318B1/en active Active
- 2009-04-16 EP EP21212873.0A patent/EP4015527A1/en active Pending
- 2009-04-16 SI SI200930931T patent/SI2268666T1/sl unknown
- 2009-04-16 CN CN200980121391XA patent/CN102066414A/zh active Pending
- 2009-04-16 KR KR1020177026920A patent/KR20170110741A/ko not_active Application Discontinuation
- 2009-04-16 DK DK09733497.3T patent/DK2268666T3/da active
- 2009-04-16 DK DK16194925.0T patent/DK3144318T3/da active
- 2009-04-16 DK DK16158141.8T patent/DK3045471T3/en active
- 2009-04-16 LT LTEP16158141.8T patent/LT3045471T/lt unknown
- 2009-04-16 AR ARP090101333A patent/AR071479A1/es not_active Application Discontinuation
- 2009-04-16 MX MX2014011348A patent/MX348622B/es unknown
- 2009-04-16 PT PT141787291T patent/PT2808340T/pt unknown
- 2009-04-16 EP EP16158141.8A patent/EP3045471B1/en not_active Revoked
- 2009-04-16 PL PL14178729T patent/PL2808340T3/pl unknown
- 2009-04-16 ES ES14178729.1T patent/ES2610277T3/es active Active
- 2009-04-16 MX MX2017007881A patent/MX355457B/es unknown
- 2009-04-18 SA SA109300228A patent/SA109300228B1/ar unknown
-
2010
- 2010-10-07 IL IL208538A patent/IL208538A/en active Protection Beyond IP Right Term
- 2010-10-14 ZA ZA2010/07373A patent/ZA201007373B/en unknown
-
2011
- 2011-01-17 HK HK11100441.2A patent/HK1146284A1/xx unknown
-
2014
- 2014-01-21 IL IL230571A patent/IL230571A/en active IP Right Grant
- 2014-06-06 CY CY20141100402T patent/CY1115413T1/el unknown
- 2014-06-09 HR HRP20140535AT patent/HRP20140535T1/hr unknown
- 2014-06-17 AU AU2014203277A patent/AU2014203277C1/en active Active
- 2014-11-14 US US14/541,852 patent/US9546204B2/en active Active
- 2014-12-10 HK HK14112411.0A patent/HK1199039A1/xx unknown
- 2014-12-25 JP JP2014262056A patent/JP2015120696A/ja active Pending
-
2016
- 2016-08-16 US US15/238,362 patent/US9771407B2/en active Active
- 2016-10-07 JP JP2016198588A patent/JP6486310B2/ja active Active
- 2016-11-16 HR HRP20161520TT patent/HRP20161520T1/hr unknown
-
2017
- 2017-05-30 HU HUS1700024C patent/HUS1700024I1/hu unknown
- 2017-05-31 HU HUS1700025C patent/HUS1700025I1/hu unknown
- 2017-06-05 LT LTPA2017018C patent/LTPA2017018I1/lt unknown
- 2017-06-06 FR FR17C1020C patent/FR17C1020I2/fr active Active
- 2017-06-06 NO NO2017025C patent/NO2017025I1/no unknown
- 2017-06-23 AU AU2017204259A patent/AU2017204259B2/en active Active
- 2017-06-23 AU AU2017204258A patent/AU2017204258B2/en active Active
- 2017-06-26 HR HRP20170958TT patent/HRP20170958T1/hr unknown
- 2017-08-01 JP JP2017148823A patent/JP6762916B2/ja active Active
- 2017-08-29 US US15/690,061 patent/US10995128B2/en active Active
- 2017-09-05 AU AU2017225020A patent/AU2017225020B2/en active Active
- 2017-09-27 LT LTPA2017029C patent/LTPA2017029I1/lt unknown
- 2017-09-27 HU HUS1700036C patent/HUS1700036I1/hu unknown
- 2017-09-28 NO NO2017050C patent/NO2017050I1/no unknown
-
2018
- 2018-11-08 RU RU2018139379A patent/RU2745557C3/ru active Protection Beyond IP Right Term
-
2019
- 2019-10-25 JP JP2019194476A patent/JP7316905B2/ja active Active
-
2021
- 2021-04-30 US US17/246,348 patent/US11952407B2/en active Active
- 2021-10-27 JP JP2021175403A patent/JP2022031652A/ja active Pending
-
2023
- 2023-12-21 JP JP2023215339A patent/JP2024038000A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140535T1 (hr) | Rekombinantni fsh ukljuäśujuä†i alfa 2,3- i alfa 2,6-sialilaciju | |
| AR125991A2 (es) | Preparación farmacéutica | |
| RS54905B1 (sr) | Poboljšani rekombinantni humani folikulo-stimulišući hormon | |
| CL2012001710A1 (es) | Anticuerpo aislado que se enlaza selectivamente a hepcidina-25 humana y cuyas hcvr y lcvr tienen las secuencias de aminoácido sec id nos:150 y 124; polinucleótido, vector; célula hospedadora; uso en el tratamiento y/o prevención de anemia; procedimiento de producción y composición farmacéutica (div. de sol. 3190-08). | |
| EP3002294A3 (en) | Peptide fragments for inducing synthesis of extracellular matrix proteins | |
| ZA200808490B (en) | Phenylamino-benzoxazole sustituted carboxylic acids, method for their production and use thereof as medicaments | |
| EP3336182A3 (en) | Modified phosphatases | |
| PL1902706T3 (pl) | Trwałe w roztworze kompozycje farmaceutyczne tetracyklin, sposób ich otrzymywania i ich zastosowania | |
| IL213039A (en) | Human anti-angiopoietin-2 antibodies, pharmacological compounds containing these antibodies, their nucleic acids encoded, and expression vectors | |
| IL192670A (en) | Carboxylic Acids of 1, 3-Dioxane, Process for Preparation, Pharmaceutical Preparations Containing and Using it for Medication | |
| SI2352386T1 (sl) | Postopek za izdelavo spojine n-maslene kisline v mikroinkapsulirani obliki za živalsko ali človeško porabo | |
| UA110323C2 (en) | Derivative of serum amyloid p and their receipt and application | |
| NZ597580A (en) | Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof | |
| IL198845A (en) | An extended-release peptide preparation, a process for its preparation and use for drug preparation | |
| WO2008052173A3 (en) | Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use | |
| HUE038174T2 (hu) | Eljárás citromsavat, magnéziumoxidot, káliumbikarbonátot és nátriumpikoszulfátot tartalmazó gyógyszertermék elõállítására, ilyen eljárással elõállított szemcsés gyógyászati készítmény és köztitermékei | |
| IL266097A (en) | Citric acid acid salt of (R)-5-((E)-2-(pyrrolidine-3-yl)vinyl)pyrimidine, a pharmaceutical preparation containing the salt, use of the salt in the production of a medicine, salt for use, and method of production | |
| HRP20180090T1 (hr) | Nove primjene hip/pap ili njihovih derivata | |
| EA201270573A1 (ru) | Гранулированный в расплаве цинакальцет | |
| JP2013542954A5 (hr) | ||
| UY29769A1 (es) | Proceso para preparar acidos y lactonas sacarinicos | |
| HRP20150968T4 (hr) | Pripravak za uporabu za liječenje neplodnosti | |
| IL217758A (en) | Polypeptides that increase glucose metabolism, their encoded nucleic acid molecules, their pharmaceutical preparations and their use in the preparation of drugs | |
| PE20091235A1 (es) | Composiciones que comprenden acido asiatico y/o acido madecasico | |
| FR2949059B1 (fr) | Procede de preparation d'un jus integral d'olive, composition obtenue selon ce procede et son application dans le domaine de la cosmetique et de la dietetique |